Clinical Trial Update: Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for Xingnaojing in moderate-to-severe acute ischemic stroke.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Xingnaojing

Snippet

Sponsor: Dongzhimen Hospital, Beijing | Conditions: Acute Ischemic Stroke | Phase 4 | Status: UNKNOWN